<DOC>
	<DOCNO>NCT01493726</DOCNO>
	<brief_summary>This study determine pharmacokinetics ( PK ) , safety , tolerability ALKS 9072 ( also know ALKS 9070 ) 4 monthly dos adult chronic stable schizophrenia .</brief_summary>
	<brief_title>A Study ALKS 9072 Subjects With Chronic Stable Schizophrenia</brief_title>
	<detailed_description>Three active treatment group placebo group plan . Randomization sequential dose level across site placebo assignment randomly insert . Each subject 's participation approximately 8 month , include screening , treatment period , 3-month follow-up period .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Diagnosis chronic schizophrenia clinically stable Body mass index ( BMI ) 18.5 35.0 kg/m2 , inclusive Stable antipsychotic medication regimen &gt; /= 2 month Screening Be willing able confine inpatient clinical research unit total 37 day course study Aripiprazole use within 30 day Screening History intolerance allergy hypersensitivity aripiprazole , excipients , antipsychotic agent , INTRALIPID ( include peanut , soy , egg , glycerol ) Current diagnosis Axis I disorder schizophrenia History seizure disorder condition associate seizure History neuroleptic malignant syndrome ( NMS ) Positive test result HIV , hepatitis B surface antigen , antihepatitis C antibodies Received medication IM injection within 30 day Screening Monoamine oxidase inhibitor ( eg , phenelzine , tranylcypromine , selegiline ) use within 30 day Screening DSMIVTR diagnosis alcohol substance dependence , exception nicotine caffeine dependence within 12 month Screening Donation blood blood component within 4 week Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>